Biomnis plans to make NIPT available in France, Genoma plans to perform NIPT services in Italy, and the Center for Human Genetics and Laboratory Diagnostics will offer NIPT in Germany.
“Biomnis evaluated the different technologies and selected Illumina because of their high level of performance as published in respected, peer-reviewed medical journals,” said Dr. Charles Woler, CEO of Biomnis Laboratories. “Backed by whole genome sequencing, we look forward to making our highly accurate test accessible to physicians and their patients.”
“We are excited to offer NIPT through our network with the use of Illumina’s technology,” said Dr. Francesco Fiorentino, CEO and Director of Genoma Group Laboratories. “After evaluating different offerings, we selected Illumina’s technology for its deep sequencing capabilities. We are continuously trying to improve our service and offerings for patients and healthcare providers, and we believe our physician customers and the expectant families they work with will be thrilled to have access to this important information in an accurate, safe, and efficient manner.”
“We decided on a partnership with Illumina because we share common values regarding delivering high quality products and services,” said Dr. Hanns-Georg Klein, CEO of the Center for Human Genetics and Laboratory Diagnostics Martinsried. “One of the reasons we founded The Prenatalis Consortium was to set standards and to further develop applications of NIPT in close cooperation with leading prenatal centers in Germany. It is crucial to integrate NIPT into the context of established prenatal diagnostics including ultrasound, invasive prenatal diagnostics, and biochemistry.”
“These agreements are another step in establishing Illumina as a global leader in reproductive and genetic health solutions and as a valued partner for NGS-based testing across a broad range of clinical applications,” said Tristan Orpin, Senior Vice President and General Manager of Reproductive and Genetic Health for Illumina.
About Biomnis
Founded in 1897 by Marcel Mérieux, Biomnis is the leading provider of medical laboratory testing services in France. With a menu of over 2,500 assays across all biomedical disciplines, including specialised testing for which we have all required authorisations, Biomnis performs over 40,000 tests per day for more than 20,000 patients. Firmly rooted in pathology testing for over 100 years, Biomnis has become one of the largest providers of specialised medical testing services both in France and internationally. Our growth is a result of our ongoing innovation and technological investments, most notably in the fields of female biology, oncology, personalised medicine, as well as molecular and chromosomal genetics.
For further information about the services we provide please visit our website www.biomnis.com
About Genoma Group
GENOMA Group is a leading molecular genetics laboratory based in Italy, internationally renowned as one of the largest, fully integrated, specialized provider of state-of-the-art genetics testing services. Widely respected for its excellence, innovation and deep scientific base, GENOMA is the center of choice for groundbreaking genetic services worldwide. Since its inception in 1998, GENOMA Group offers private laboratories, public hospitals, physicians and patients, a broad range of genetic tests, over 1.200 tests covering 18 different areas in the field of molecular diagnostics.
For more information visit www.laboratoriogenoma.eu/eng
About The Center for Human Genetics and Laboratory Diagnostics Martinsried
The Center for Human Genetics and Laboratory Diagnostics in Martinsried near Munich was founded in 1998 as a spin-off from the Institute of Clinical Chemistry at the University Hospital Grosshadern of the Ludwig-Maximilians University. The facility is specialized in genetic and immunological diagnostics.
For more information visit www.medical-genetics.de
Forward-Looking Statements
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
_____________________________________